Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Enzo Life Sciences Launches New Compound Library to Provide Essential Standards for Cancer Inhibitor Screening

Enzo Life Sciences is proud to introduce the SCREEN-WELL® Cancer Library, a collection of 275 ready-to-use compounds for use in cancer inhibitor screening and assay development.

The SCREEN-WELL® Cancer Library is comprised of compounds that are dissolved at 10 mM in DMSO and aliquoted at 100 µL per well in deep 96-well plates. It contains small molecules affecting mTOR, aurora kinases, tyrosine kinases, PI3K, HDAC, and other differing compound classes. The structural and mechanistic differences between compounds as well as the inclusion of nontoxic controls make the library a vital tool in cancer drug discovery and screening.

The SCREEN-WELL® Cancer Library builds upon Enzo’s collection of cancer research solutions which includes DNA labeling kits for genomic analysis, enzyme activity kits, detection kits for cellular analysis, and immunoassays and antibodies for biomarker detection.

The comprehensive SCREEN-WELL® Cancer Library is the newest addition to Enzo’s portfolio of SCREEN-WELL® Compound Libraries, which are unique collections of small molecules provided in a ready-to-use format, amenable to high-throughput screening. The SCREEN-WELL® Compound Libraries include complete documentation that highlights the physical information and mechanism of action for each compound. In addition, Enzo has the ability to re-supply individual bulk compounds or to build custom libraries. Our extensive list of compound libraries includes the SCREEN-WELL® FDA approved drug library, toxicity libraries, kinase inhibitor libraries, and more.

About Enzo Life Sciences

Enzo Life Sciences, Inc. is a wholly owned subsidiary of Enzo Biochem, Inc. headquartered in Farmingdale, New York. Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products and services that meet the ever-changing and rapidly growing needs of healthcare. Underpinning Enzo Biochem’s technologies, platforms and products is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
Enzo Life Sciences, Inc. is a pioneer in labeling and detection technologies from genome to whole cell across research and diagnostic markets. We are focused on providing cost-effective, relevant and reliable solutions for life science research, drug development, and clinical research. We are organized to lead in the development, production, marketing, and sales of innovative research tools worldwide based on 40 years’ experience in building strong global market recognition and implementing outstanding operational capabilities.

New Product Release
Date: January 19th 2017

For additional Information, please contact:
Kara Cannon, Global Head of Marketing
1-631-694-7070 x 1301

Recommend this page